Improving adherence to medication via smarter, patient-centric pharmaceutical packaging and extracting further value from existing medicines and delivery devices are two of the latest key strategies aimed at reducing waste and protecting the bottom line, according to experts at the recent Pharmapack Europe (#pharmapackeu). The event is widely seen as a yardstick of the industry’s prospects for the year ahead. The event plans to host a record 411 exhibiting companies, 5366 attendees and 325 delegates.
The event took place at the Paris Expo, Porte de Versailles, February 5-6 and featured many innovations as well as novel drug delivery systems, with waste management, connectivity, and patient centricity being some the key themes throughout this year’s edition.
A “who’s who” of pharma packaging and drug device innovators was exhibited from Aptar, SHL, Stevanato Group and BD to Nemera and West Pharmaceutical Services—with several major new technologies and partnerships announced. But some of the most promising innovations were presented by emerging companies in the Start-up hub—with technologies featured from AI development platforms through miniaturized/non-intrusive sensors, to vial/ampule combination devices, and smart packaging.
The conference focused on four themed content sessions, while the learning labs and several educational and interactive workshops explored major industry changes that lie ahead. Aurelio Arias, engagement manager at IQVIA, suggested during his session that “the future of Value-Added Medicines is not just driven by deeper Insights and data capture but will also see gamification transforming engagement of therapies.” Arias added that “while patients are concerned about the security and the custodianship of their data,” they are still actively using connected devices. As a result, the natural evolution of this trend could be that healthcare companies will increasingly incentivize better compliance through gamification.
In the ‘Challenges in drug delivery for biologics’ session, experts agreed that combining biologic drug and device development, while meeting regulatory standards, is a significant learning curve for the industry.
In the ‘Challenges in drug delivery for biologics’ session, experts agreed that combining biologic drug and device development, while meeting regulatory standards, is a significant learning curve for the industry. Overall, drug delivery was seen as increasing integral to the growth of the biologics market, with patient centricity as an essential component in adherence. In the short term, this is projected to push manufacturers to provide better devices that ease the patient experience. But in the long term, experts postulated connected devices will play a major role in the advancement of the biologics industry—with increasing levels of vital data on how devices are used post launch.
In the ‘New horizons in innovation’ session, Marc Rohrschneider, head New Technologies, Device Development, and Commercialization at Novartis AG predicted that with pharma now having access to technology to connect boxes, vials, and devices to networks, the next decade is not about the technology challenges. It will instead explore how the industry safeguards data, and ultimately, who is its custodian. Blockchain is another industry buzzword of the last year, but experts at Pharmapack point to the improved accountability it could provide in pharma supply as its most immediate use, rather than in securing patient data. “You should think of it as the most secure audit trail you can have. Immutable, temporal, and despite what many have said, scalable,” said Jason Lacombe, chief executive officer, Veratrak. But the key to delivering on its potential, according to Lacombe, is for pharma and tech communities to work closer together to deliver over the hype.
Silvia Forroova, brand director at Pharmapack Europe said, “In the last few years, as our Pharmapack agenda is testament to, we have seen the rise of truly patient centric delivery forms, increasingly smart and child-safe packaging, and a growing awareness of the vital role we can play in bringing about a more environmentally friendly industry. But what we are also seeing is that by bringing different groups together we are reinventing the art of the possible. It’s one of the greatest strengths of Pharmapack that we provide a platform to help build networks and communities, share learning and celebrate new innovations. Our experience of this event in 2020 is that the industry looks well set for growth in the year ahead and we can expect to see more collaborations in an age when the delivery of products is changing quickly. This is great news for drug delivery and packaging companies, but even better news for patients.”
Pharmapack Europe 2021 will return to the Paris Expo, Porte De Versailles in Paris 27-28 Jan. To exhibit at next year’s show, click here.
